Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

NCT07339059 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer ( SCLC )
Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Interventions

DRUG: Sacituzumab govitecan
DRUG: Atezolizumab
DRUG: Durvalumab

Sponsor

Bindu R Potugari

Collaborators

[object Object]